Resource Summary Report

Generated by dkNET on Sep 6, 2026

NCI-H522

RRID:CVCL_1567
Type: Cell Line

Proper Citation

RRID:CVCL_1567

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1567

Proper Citation: RRID:CVCL_1567

Description: Cell line NCI-H522 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:1311061, PMID:1563005, PMID:1565469, PMID:2041050, PMID:2388294, PMID:3335022, PMID:7718330, PMID:8806092, PMID:9331090, PMID:10700174, PMID:11030152, PMID:15748285, PMID:15900046, PMID:17088437, PMID:18277095, PMID:19153074, PMID:19372543, PMID:19472407, PMID:20164919, PMID:20215515, PMID:20557307, PMID:22068913, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:22961666, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:29444439, PMID:29681454, PMID:30710758, PMID:30894373, PMID:31068700, PMID:31733513, PMID:31803961, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Donor information: Established from a 60 packs per year smoker (ATCC=CRL-5810)., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H522

Synonyms: NCI.H522, H522, H-522, NCI-522, NCI522, NCIH522

Cross References: BTO:BTO_0003536, CLO:CLO_0008094, EFO:EFO_0002295, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5810, BioSample:SAMN03471314, BioSample:SAMN10988279, cancercelllines:CVCL_1567, Cell_Model_Passport:SIDM00116, ChEMBL-Cells:CHEMBL3308392, ChEMBL-Targets:CHEMBL614387, CLS:305279, Cosmic:875853, Cosmic:877409, Cosmic:897509, Cosmic:903576, Cosmic:905944, Cosmic:974294, Cosmic:980965, Cosmic:1004696, Cosmic:1032437, Cosmic:1044246, Cosmic:1092622, Cosmic:1146919, Cosmic:1154592, Cosmic:1175866, Cosmic:1188591, Cosmic:1219062, Cosmic:1239883, Cosmic:1305350, Cosmic:1312335, Cosmic:1436012, Cosmic:1802320, Cosmic:1870276, Cosmic:1891886, Cosmic:1995582, Cosmic:1998464, Cosmic:2125185, Cosmic:2772155, Cosmic-CLP:905944, DepMap:ACH-000343, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905944, GEO:GSM2101, GEO:GSM50217, GEO:GSM50280, GEO:GSM206495, GEO:GSM274753, GEO:GSM274754, GEO:GSM353230, GEO:GSM434309, GEO:GSM513965, GEO:GSM514350, GEO:GSM743456, GEO:GSM750798, GEO:GSM784233, GEO:GSM794291, GEO:GSM799344, GEO:GSM799407, GEO:GSM827479, GEO:GSM847077, GEO:GSM887434, GEO:GSM888514, GEO:GSM1153415, GEO:GSM1178491, GEO:GSM1178492, GEO:GSM1181345, GEO:GSM1181346, GEO:GSM1374751, GEO:GSM1374752, GEO:GSM1374753, GEO:GSM1670248, GEO:GSM2124677, IARC_TP53:520, IARC_TP53:21410, IGRhCellID:NCIH522, KCLB:25810, KCLB:90522, LiGeA:CCLE_084, LINCS_LDP:LCL-1622, NCI-DTP:NCI-H522, PharmacoDB:NCIH522_1118_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD011315, PRIDE:PXD030304, Progenetix:CVCL_1567, PubChem_Cell_line:CVCL_1567, SKY/M-FISH/CGH:2803, Wikidata:Q54908074

ID: CVCL_1567

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181246+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H522.

Warning: Discontinued: KCLB; 25810
Donor information: Established from a 60 packs per year smoker (ATCC=CRL-5810)., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Chuikov S, et al. (2026) E2A selectively regulates TGF-??-induced apoptosis in KRAS-mutant non-small cell lung cancer. Molecular oncology, 20(7), 1877.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. Cell reports, 45(6), 117427.

Arora P, et al. (2025) Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. Journal of virology, 99(2), e0123024.

Gesmundo I, et al. (2025) Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells. International journal of molecular sciences, 26(7).

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Srivastava PP, et al. (2025) Epigenetic co-regulator HCF-1 promotes lung cancer via O-GlcNAcylation-dependent pathways. Molecular therapy. Oncology, 33(4), 201046.

Zhang L, et al. (2024) ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralization. PLoS pathogens, 20(11), e1012653.

Geroyska S, et al. (2024) N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. Cancer research communications, 4(7), 1815.

Horie M, et al. (2024) Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. Molecular oncology, 18(1), 21.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Kweon TH, et al. (2024) O-GlcNAcylation of RBM14 contributes to elevated cellular O-GlcNAc through regulation of OGA protein stability. Cell reports, 43(5), 114163.

Ando T, et al. (2024) NECTIN2 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma. Respiratory investigation, 62(4), 582.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Lal S, et al. (2023) Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor. Cancer research

communications, 3(9), 1731.

Chow A, et al. (2023) The ectonucleotidase CD39 identifies tumor-reactive CD8+ T??cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity, 56(1), 93.

Kennedy PR, et al. (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Frontiers in immunology, 14, 1060905.

Sun L, et al. (2022) Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells. Molecular cancer research : MCR, 20(12), 1785.

Puray-Chavez M, et al. (2021) Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell reports, 36(2), 109364.

Caeser R, et al. (2021) MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience, 24(11), 103224.

Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell, 184(12), 3163.